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Abstract Essential hypertension, insulin resistance, heart
failure, congestion, diuretic resistance, and functional renal
disease are all characterized by excessive central sympa-
thetic drive. The contribution of the kidney’s somatic
afferent nerves, as an underlying cause of elevated central
sympathetic drive, and the consequences of excessive
efferent sympathetic signals to the kidney itself, as well as
other organs, identify the renal sympathetic nerves as a
uniquely logical therapeutic target for diseases linked by
excessive central sympathetic drive. Clinical studies of renal
denervation in patients with resistant hypertension using an
endovascular radiofrequency ablation methodology have
exposed the sympathetic link between these conditions.
Renal denervation could be expected to simultaneously
affect blood pressure, insulin resistance, sleep disorders,
congestion in heart failure, cardiorenal syndrome and
diuretic resistance. The striking epidemiologic evidence for
coexistence of these disorders suggests common causal
pathways. Chronic activation of the sympathetic nervous
system has been associated with components of the meta-
bolic syndrome, such as blood pressure elevation, obesity,
dyslipidemia, and impaired fasting glucose with hyperin-
sulinemia. Over 50% of patients with essential hypertension
are hyperinsulinemic, regardless of whether they are
untreated or in a stable program of treatment. Insulin
resistance is related to sympathetic drive via a bidirectional
mechanism. In this manuscript, we review the data that
suggests that selective impairment of renal somatic afferent
and sympathetic efferent nerves in patients with resistant
hypertension both reduces markers of central sympathetic
drive and favorably impacts diseases linked through central
sympathetics—insulin resistance, heart failure, congestion,
diuretic resistance, and cardiorenal disorders.
Keywords Sympathetic nervous system  Hypertension 
Insulin resistance  Sleep apnea  Congestion 
Heart failure  Cardiorenal syndrome  Tachycardiac
arrhythmias  Renal denervation  Symplicity HTN-2
Introduction
The contribution of renal somatic afferent nerves to central
sympathetic drive and the impact of excessive efferent
sympathetic signaling to the kidney are intimately linked to
the development of several chronic diseases associated
with such sympathetic excess [1, 2]. These chronic
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ailments, essential hypertension, insulin resistance, con-
gestion, diuretic resistance and cardiorenal disorders, have
a multiplicity of underlying etiologies, yet their shared link
with elevated central sympathetic drive identifies a com-
mon therapeutic target [3–5]. Therefore, treatment of the
elevated sympathetic activity would be anticipated to
provide significant clinical benefit. Recently, a new
approach to selectively denervate the kidneys by ablation
of efferent sympathetic and afferent somatic fibers has been
established in clinical practice [6]. This article summarizes
the chronic diseases linked by increased central sympa-
thetic drive by describing the organ specific consequences
of increased efferent signaling, and further suggests a
common role of renal somatic afferents in elevation of
central drive.
Renal somatic afferent nerve activity as a source
of central sympathetic drive
The sophisticated network of afferent and efferent sensory,
chemo- and baroreceptor nerve fibers, lie netlike in the
adventitia of the renal artery (Fig. 1) and throughout the
kidney [7]. Their signaling pathway to the hypothalamus
provides the basis for targeting these nerves’ as modulators
of central integration in the brain stem [2] (Fig. 2). Altering
the signals from the kidney to the hypothalamus is
expected to impact peripherally, including on arterial
resistance, the venous capacitance vasculature, peripheral
and central chemoreceptors, sympathetic activity of the
kidney, the liver and of course the heart itself [8]. Reduc-
tion of central sympathetic tone is therefore expected to
simultaneously impact the plethora of systemic disorders
linked through inappropriately high central sympathetic
activity. Activation of renal sensory afferent signaling is
likely caused by various stimuli such as renal ischemia,
hypoxia, and oxidative stress as well as intrinsic renal
diseases [2]. In the 5/6 nephrectomy rat model of chronic
renal failure and hypertension dorsal rhizotomy prevented
blood pressure elevation indicating that afferent signaling
from the diseased kidney to central integrative structures
contributes to the rise in blood pressure in kidney disease
[9]. Renal injury caused by unilateral phenol injection
reliably causes hypertension in rats and is associated with
both an increase in norepinephrine secretion from the
posterior hypothalamus and increased renal sympathetic
efferent and afferent nerve activity of both kidneys [10].
Surgical renal denervation of the phenol-treated kidney
prevents hypothalamic-mediated rises in noradrenaline and
increases in blood pressure, while restoring vascular
resistance to normal. These findings have been confirmed
in several other models of renal disease as well as inter-
ventions targeting the sympathetic nervous system, thereby
demonstrating the crucial role of both efferent and afferent
renal nerve signaling in hypertension associated with
chronic kidney disease [11]. Experiments based on the
same principles conducted in humans using nephrectomy
in end stage renal disease patients with and without
transplant have demonstrated similar findings [12].
Nephrectomy of the native non-functioning kidney has
resulted in reduction of muscle sympathetic nerve activity,
reduction of total body noradrenaline spillover, reducing
blood pressure and calf vascular resistance, confirming the
role of the diseased kidney in mediating central sympa-
thetic tone.
The invasive nature of nephrectomy or spinal rhizotomy
has recently been superseded by endovascular renal spe-
cific denervation of native kidney using low power radio-
frequency in end stage renal disease patients either on
dialysis or post transplant as well as patients with hyper-
tension resistant to pharmacologic therapy [13]. Following
endovascular denervation, blood pressure fell significantly,
and, when measured, muscle sympathetic nerve activity
had returned to normal post denervation [14–16]. Similar
findings of reduced total body noradrenaline spillover and
Fig. 1 Renal artery of a Sprague–Dawley rat, stained with tyrosin
hydroxylase antibody. Red tyrosine hydroxylase, green a-smooth
muscle actin, blue DAPI. Unpublished data by Mahfoud F, Kasakow
A, Bo¨hm M
Fig. 2 Renal somatic afferent nerve activity, a source of elevated
central tone
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reduced muscle sympathetic nerve frequency in resistant
hypertension patients without evident renal disease suggest
the renal chemo- or baroreceptors are responding to stimuli
other than overt renal damage, possibly local metabolites
of ischemia or hypoxia [14]. While renal generated NO,
adenosine, and angiotensin II may be responsive to changes
in central nervous system status, these animal and human
experiments strongly identify a direct neurologic link.
These numerous observations, confirm the native kidney as
a neurologic progenitor of signals to the central sympa-
thetic nervous system.
Consequences of increased central sympathetic tone
Increased renal sensory afferent signaling, following its
integration in the posterior hypothalamus, directly influ-
ences central sympathetic outflow, not only restricted to the
kidneys but evident throughout the entirety of the sympa-
thetic system [1] (Fig. 3). Outbound sympathetic nerve
fibers innervate all organs that are involved in the direct
control of peripheral vascular resistance, management of
central and peripheral chemo receptors, directly influence
cardiovascular contractility, heart rate and rhythm, man-
agement of total body salt and water through both renal
mechanisms and control of intravascular circulating blood
volume through alterations in tone of the splanchnic stor-
age vessels and of course the kidney itself [2]. Thus,
reduction of excessive central sympathetic activity, fol-
lowing the selective removal of renal signals to the hypo-
thalamus, is therapeutically attractive in the treatment of
disorders commonly linked by sympathetic over-activity
[17]. The consequences of elevated central sympathetic
drive underlie the many diseases that are found to cluster
with hypertension and systolic heart failure, such as insulin
resistance, sleep disorders, diuretic resistance and conges-
tion [18].
Specific consequences of increased sympathetic efferent
signaling to the kidney
The sympathetic nerves to the kidneys terminate in the
blood vessels, the juxtaglomerular apparatus, and the renal
tubules [19]. Stimulation of the renal sympathetic nerves
cause increased renin release, increased sodium reabsorp-
tion, and a reduction of renal blood flow [2]. These nerves,
exclusively noradrenergic, have a graded response to nerve
stimulation including increased renin secretion rate;
increased proximal tubular sodium reabsorption; and direct
adrenergic-mediated increases in renal vascular resistance.
It has been discussed that essential hypertension is largely
neurogenic, both initiated and sustained by sympathetic
nervous system over-activity proved with studies using
radiotracer dilution methodology measuring spillover of
noradrenaline from the kidney to plasma [3, 20–22].
Beyond essential hypertension, efferent sympathetic traffic
is logically linked with the three major physiologic features
identified as the renal component of the ‘‘cardiorenal syn-
drome’’ [23, 24]: excess renin release, rightward shift of
the pressure-natriuresis relation and reduced renal blood
flow and glomerular filtration rates. These three conse-
quences of heightened sympathetic tone to the kidney
portend heightened morbidity and mortality rates.
Efferent sympathetic nerve activity is increased in sys-
tolic heart failure, as demonstrated by an excessive
increase of noradrenaline synaptic spillover to plasma from
both the heart and kidney [23]. Intravenous infusion of the
centrally acting alpha adrenoceptor agonist clonidine, at
modest doses, significantly attenuates cardiac and renal
sympathetic tone in heart failure patients [25]. Beyond the
noted beneficial cardiac effects of antiadrenergic therapy in
heart failure, the renal sympatholytic effects counteract
direct neuro-mediated tubular salt retention. Consistent
with this notion is the predictive value of renal sympathetic
activation on all-cause mortality or need for heart trans-
plant in patients with congestive heart failure [26]. The
contribution of increased renal noradrenaline spillover in
heart failure as a predictor of mortality is independent of
overall sympathetic activity, glomerular filtration rate, and
left ventricular ejection fraction [23]. Evidence-based
treatment with beta-blockers in patients with chronic heart
failure reduces morbidity and mortality, due to blockade of
the effects of excessive sympathetic activation on the heart
[27, 28]. These findings suggest treatment strategies that
further reduce renal sympathetic activation, and in partic-
ular renal sympathetic efferent signals, have the potential
to improve survival in patients with heart failure.
Fig. 3 Cardiovascular consequences of chronic elevated central
sympathetic signaling
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Both advanced chronic kidney disease and end stage
renal disease are characterized by heightened efferent
sympathetic nervous system activation [29]. Centrally
acting sympatholytic agents, such as moxonidine delay the
progression of renal failure, and reduces MSNA in nor-
motensive patients with type I diabetes mellitus, in the
absence of blood pressure changes [7, 30, 31].
Consequences of chronic elevated central
sympathetic tone
Essential hypertension
Bilateral renal denervation prevents or attenuates the
development of hypertension in a large number of diverse
animal models of experimental hypertension including
genetic, salt sensitive, obesity related, renovascular, and
other hypertension models [2, 32–34]. Only models of
volume expansion with hormonal activation, such as the
one-kidney, one-clip model of hypertension, are associ-
ated with elevated blood pressure in the absence of
involvement of the renal sympathetic axis [35]. In other
models, the renal sympathetic axis causes, promotes or
sustains blood pressure across species and hypertension
models. These findings corroborate the notion that renal
sympathetic nerves represent a critical link between the
sympathetic nervous system and the kidney in essential
hypertension.
Approximately 70% of incident hypertension is asso-
ciated with overweight and obesity [36]. The potential
for renal denervation to treat obesity-related hypertension
has been investigated in a chronically instrumented,
high-fat fed dog model, which is characterized by sodium
retention and increased sympathetic nervous system
activation [34]. Whilst the high fat diet resulted in a 50%
increase in body mass in both control and denervated
dogs, blood pressure increased significantly only in the
control but not in the denervated dogs. Furthermore,
sodium retention was reduced by 50% in the denervated
dogs. Extension of this principle to man has been dem-
onstrated in the Symplicity HTN-2 trial of therapeutic
renal denervation in resistant hypertension. Patients
failing to attain blood pressure control, despite an aver-
age of more than five medications, experienced a
6 months reduction of office blood pressure by -32/-12
mmHg compared to well-matched controls [16]. With a
mean body mass index of 31 kg/m [2] most of the
included patients were overweight or obese. The reduc-
tion of blood pressure alone is anticipated to have sig-
nificant impact on the risk of developing cardiovascular
diseases in these patients.
Obstructive sleep apnea in resistant hypertension
Obstructive sleep apnea, often considered a cause of
resistance in patients with essential hypertension, may also
be a consequence of increased central sympathetic tone
[37, 38]. A recent observational series of patients with
sleep study pre and post renal denervation for resistant
hypertension suggests that denervation and/or blood pres-
sure reduction alone reduces the frequency of apneic–
hypopneic episodes [39]. Reduction of renal mediated salt
and water expansion, a consequence of reducing renal
sympathetic efferent signaling and neurologic mediated
volume expansion [38], could be expected to reduce the
occurrence or severity of obstructive sleep apnea in
patients with overt or those with subtle volume expansion.
Patients with obstructive sleep apnea have elevated muscle
sympathetic nerve activity [40], which is reduced following
adequate treatment of the obstruction. The suggestion that
it is the over-activity of the sympathetic system that
underlies some of the obstruction needs further testing.
Insulin resistance
That insulin resistance has been found in lean as well as in
weight matched hypertensives suggests that insulin resis-
tance is related to the basic determinates of blood pressure
[41]. Julius et al. [42] proposed in 1991 that pressure
induced restriction of the microcirculation limits nutritional
flow, and thereby impairs glucose uptake in the skeletal
muscle. While other factors are likely operative, two recent
studies have observed profound changes in insulin resis-
tance following renal denervation for the treatment of
resistant hypertension [43, 44]. Euglycemic hyperinsuli-
nemic clamp studies in conjunction with assessment of
total body noradrenaline spillover and muscle sympathetic
nerve activity before and after renal denervation in patients
with polycystic ovary syndrome demonstrated an associa-
tion between reduction of total body spillover, sympathetic
nerve activity and improved insulin sensitivity measured
with clamp [44]. A second and larger series, in resistant
hypertensive patients undergoing renal denervation has
documented a dramatic change in fasting insulin, C-peptide
and calculated HOMA-IR with 20% of patients were
documented to improve diabetic status (from glucose
intolerance to normal or from diabetes to glucose intoler-
ance) 3 months after renal denervation [43]. Beyond
questions of insulin level and diabetic risk, the application
of renal denervation to prevent development of structural
renal changes due to early diabetic nephropathy has
previously been explored [45]. Functional and anatomic
studies performed 2 weeks after the onset of streptozotocin-
induced diabetes in denervated rats revealed attenuation of
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physiologic and anatomic findings of early diabetic
nephropathy. Studies in humans demonstrated that sym-
pathoinhibition with the centrally acting drug moxonidine
reduced microalbuminuria in normotensive patients with
type 1 diabetes, in the absence of any significant blood
pressure changes [30]. Both the change in diabetic state
and the profound reduction of insulin levels in these initial
reports may have profound implications on cardiovascular
risk. The calculated 10-year change in cardiovascular risk
associated with blood pressure reduction and improvement
in diabetic state appears to be more than additive. Pre-
clinical observations on renal protection against diabetic
glomerular sclerosis coupled with the human data on renal
denervation resulting in reduced blood pressure with
improved insulin sensitivity justify additional study in this
area.
Congestion
Heart failure associated with reduced systolic function or
congestion (or both) is characterized by substantial neuro-
hormonal activation in heart, kidney and skeletal muscle
[23, 46]. These neurohumoral responses include activation
of the sympathetic nervous system and the renin–angio-
tensin–aldosterone system, further aggravating heart failure
by increasing ventricular afterload and preload. Initial
measures of serum noradrenaline verified an inverse rela-
tion between serum levels and mortality, which was ini-
tially hypothesized to be a hormonal marker of
hemodynamic stress, and later with the appreciation of the
value of beta blockers to improve morbidity and mortality
in heart failure, felt to itself be a mediator of the increased
mortality rates [47, 48]. Moreover, renal noradrenaline
spillover is an independent predictor of heart transplant
free survival; patients with elevated serum norepinephrine
experience rates of mortality three times higher in
untreated than treated heart failure patients [2, 23, 49].
Renal sympathetic efferent traffic can underlie congestion
due to frequency dependent release of renin, sodium
retention in the proximal tubules and elevation of renal
vascular resistance [2]. Renin release, and subsequent
generation of local angiotensin II directly stimulates
proximal tubular sodium reabsorption by activating sodium
bicarbonate co-transporters and sodium hydrogen exchange
[50] and also by causing vasoconstriction of the efferent
renal arteriole, lowering peritubular hydrostatic pressure
[51]. Aldosterone, acting within the distal tubule and col-
lecting duct, up-regulates and activates the basolateral Na/
K pumps retaining remaining intraluminal Na. The clinical
importance of the sympathetically mediated impact on fluid
retention is evident even after standing, which increases
renal sympathetic efferent signaling in heart failure and
hepato renal syndrome [2]. Upright posture alone decreases
eGFR and raises plasma concentrations of noradrenaline,
renin and aldosterone in both hepato renal and heart failure
patients [52]. The effects of chronic activation of efferent
renal signaling on total body Na and water balance are
likely critical in edema and congestion formation. The
natriuretic peptides are considered markers of volume
expansion, however, they may also serve as indicators of
excess renal efferent signaling [53]. The natriuretic actions
of natriuretic peptides are reduced in heart failure. The-
matically, the family of natriuretic peptides may represent
compensation to the anti natriuretic consequences of renal
sympathetic activity and other activated vasoconstrictor
systems. Experimental ligation of renal nerves protects
against development of postprandial natriuretic resistance
and the development of congestion or rises in ventricular
filling pressures [54]. The therapeutic value of renal
denervation in heart failure was evaluated in a similar
experimental model of coronary ligation induced myocar-
dial infarction in rats [55]. This study, in which renal
denervation was performed pre-onset of myocardial
infarction, demonstrated reduced ventricular filling pres-
sure and improved ventricular function compared to non-
denervated controls [55]. More recently, evidence from a
rabbit model with pacing induced heart failure demon-
strated that the reduction in renal blood flow and the
increase in renal vascular resistance can be prevented by
surgical renal denervation, indicating that renal sympa-
thetic nerve activity elicits a detrimental effect on renal
blood flow [56]. Equally important in this later study,
expression of angiotensin receptors was found to be
dependent on sympathetic innervation [57]. Beyond renal
management of volume, the appreciation that circulating
blood volume can abruptly be altered by neurologically
recruiting splanchnic venous storage blood pools suggests
that increased central sympathetic drive has potential to
both increase total body salt and water through renal
mechanisms as well as abruptly change circulating volume
by recruiting splanchnic venous stores of blood [2]. This
neurogenic mechanism may explain the often clinically
frustrating finding in patients who experience dramatic
increases in dyspnea and pulmonary congestion in the
absence of either weight changes or abnormalities of ven-
tricular function, i.e. sympathetically mediated changes in
circulating volume.
Central sympathetic control of sensory afferent
receptors—sympathetic underpinnings of central sleep
apnea and dyspnea
Like the peripheral pO2 receptor, the central pCO2 receptor
set point and gain are sympathetically modifiable [58];
suggesting that the clinical appreciation of dyspnea may
reflect sympathetic hyperactivity quite independent of the
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mechanism by which alveolar and interstitial lung water
stimulate interstitial pulmonary juxtacapillary receptors. A
leftward shifted set point of the central pCO2 receptor in
heart failure is well recognized, as the chronic metabolic
alkalosis is ubiquitous, and on occasion the development of
central sleep apnea, a manifestation of the shift being so
leftward that the trigger point for inspiration is not reached
[59]. Certainly, restoring a normal set point and gain of the
central pCO2 receptor from the pathological altered set
point could obliterate central sleep apnea. Dyspnea is most
often considered a consequence of increased alveolar and
interstitial lung water, however, it is not significantly
improved following diuretic therapy except in the patient
with alveolar water [60]. On the other hand, dyspnea is
principally a consequence of hypersensitivity to pCO2. If
renal denervation can restore normal minute ventilation
response to pCO2, then this direct consequence of diastolic
and systolic heart failure, i.e. exercise intolerance, may be
amenable by renal denervation.
Diuretic resistance and the cardiorenal syndrome
Escalating doses of diuretics are associated with worsening
prognosis in heart failure [61, 62]. Although generally
interpreted as a sign of worsening intrinsic heart function,
the resistance to diuretics, in particular furosemide, may
indeed reflect renal sympathetic mediated Na reabsorption
proximal to the more distal sites of furosemide action [63].
Thus, congestion and natriuretic resistance may reflect
underlying increased renal sympathetic activity. This
principle has been previously observed following the
increase of renal sympathetic signaling associated with
standing in patients with either heart failure or hepatorenal
syndrome [52]. The consequences of increased renin
release associated with renal sympathetic activity,
increased angiotensin II and aldosterone, both act to
increase salt and water retention and interfere with phar-
macologic intervention [1]. Worsening renal function
observed in heart failure patients is associated with
increased morbidity and mortality. In a pacing rabbit heart
failure model, the elevations of renal resistance and
reduction of blood flow observed with the development of
heart failure were entirely restored to normal following
renal denervation [57]. Additionally, renal AT1R expres-
sion was increased by approximately 67% and AT2R
expression was decreased by approximately 87% in rabbits
with heart failure. In contrast, kidneys from denervated
rabbits with heart failure showed a near normalization in
the expression of these receptors [57]; suggesting that the
renal hormonal milieu is in large part consequent upon
underlying renal sympathetic efferent state. The best-
described consequence of cardiorenal disease is the stag-
gering prevalence of cardiovascular mortality seen in
patients with either chronic or end stage renal disease or
both [24]. The possible clinical value of therapeutic native
kidney denervation or nephrectomy for the attenuation of
cardiovascular disorders remains entirely unexplored, yet
the ease and reported safety of the endovascular therapeutic
renal denervation may allow this experiment to be con-
ducted with relatively little risk to the end stage renal
disease patient.
Tachycardiac arrhythmias
Both atrial and ventricular arrhythmias are associated with
sympathetic hyperactivity [64, 65]. The sinus tachycardia
of heart failure may represent primary elevations of cardiac
efferent signaling. Recent studies of drugs that reduce heart
rate without additional systemic effects have demonstrated
improvements of cardiovascular mortality in heart failure
similar to the findings of beta-blockers, which also reduce
heart rate [66, 67]. The ventricular response rate in atrial
fibrillation is often an expression of sympathetic state. The
underlying ventricular rate in atrial fibrillation has been
observed to fall following renal denervation in resistant
hypertension (Felix Mahfoud, personal communication).
While this may represent changes in myocardial work and
stress associated with blood pressure declines, there may
also be reductions in direct cardiac sympathetic signaling.
Similarly, left stellate cardiac ganglionectomy has been
reported to both reduce heart rate and shorten the QT
interval [68].
From theory to practice
Reduction of central sympathetic activity following baro-
receptor stimulation has been reported with the Rheos
baroreceptor stimulator, and this carotid strategy may
indeed exhibit similar systemic properties. Further, the
reduction of central sympathetic stimulation associated
with nerve stimulation from the carotid sinus may result in
substantially reduced renal sympathetic efferent signaling
[69]. Therapeutic renal denervation has been applied in a
controlled randomized trial for the treatment of resistant
hypertension with a significant reduction of systolic blood
pressure, diastolic pressure and pulse pressure at 6 months
[16]. Reduction of insulin resistance has been anticipated in
preclinical work, and confirmed in man using gold standard
euglycemic hyperinsulinemic clamp and the calculated
HOMA-IR in two different models of excess sympathetic
state [43, 44]. While this confirms the hypothesis, pro-
spective randomized clinical trials remain to be conducted
and are currently underway. Sleep disorders, similarly may
be a reflection of the underlying sympathetic state, and a
logical diagnostic and treatment strategy may target
1054 Clin Res Cardiol (2011) 100:1049–1057
123
treatment of the sympathetic state, and later consideration
of supplemental ventilator support. Certainly, the conges-
tion that accompanies systolic and diastolic heart failure
may be mediated in part by neurologic mechanisms.
Removal of both the renal somatic afferent and sympa-
thetic efferent conduction may address both the total body
excess volume and the maldistribution of stored blood.
Lastly, the functional renal component of cardiorenal
syndrome, including diuretic resistance, may indeed be an
immediate reflection of the functional efferent renal sym-
pathetic activity, and a clinical trial to discern this physi-
ology in humans is shortly to begin.
Conclusions
Afferent somatic signals arising from the kidney and
efferent sympathetic activity to the kidney can mediate
effects on wide range of chronic conditions. Interventional
renal denervation has been shown to successfully reduce
blood pressure and improve insulin resistance in patients
with resistant hypertension. Further investigations are
needed to study the effects of selective renal denervation in
other entities linked by elevated sympathetic activity.
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